Breakthrough in antimicrobial resistance

Lixa has uncovered a novel mechanism of action that switches bacteria from resistant-state to sensitive, from biofilm to planktonic, and from untreatable to simply treatable with existing antibiotics below clinical break point. We have 2 lead drug candidates, labelled as universal antimicrobial resistance breakers (uARB), in preparation for Phase 2 clinical trials for oral, intravenous and inhaled drug administration routes. The technology is scalable across human health, animal health, crops, consumer products and industrial anti-foul applications, does not require susceptibility diagnostics and underpins a discovery platform for the uARB drug library expansion. By reversing resistance, Lixa aims to move the needle on the AMR crisis by decades.

Why work with us

Lixa has a unique technology with the potential to shape the antibiotic market, a market that has been broken for many years. Our small molecules are highly tolerable, easy to integrate into SoC and compatible with different classes of antimicrobials, including old and new antibiotics, biocides, surfactants and antiseptics. We seek partners to deploy the technology across multiple markets.